Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
Vor Bio (Nasdaq: VOR) has appointed Dr. Navid Z. Khan as Chief Medical Affairs Officer. With over 20 years of experience, Dr. Khan brings extensive expertise in medical affairs, commercial operations, and R&D. He has overseen 40+ development programs and led seven successful product launches in rare neurology and immunology indications.
Most recently at argenx, Dr. Khan headed the Neuromuscular Therapeutic Area, Medical Affairs, where he led four launches of VYVGART® products. His previous roles include leadership positions at Akouos Inc. and Sarepta Therapeutics, where he was instrumental in launching three Duchenne muscular dystrophy therapies and preparing the company's Medical Affairs organization for gene therapy programs.
Vor Bio (Nasdaq: VOR) ha nominato Dr. Navid Z. Khan come Chief Medical Affairs Officer. Con oltre 20 anni di esperienza, il Dr. Khan porta una solida expertise in affari medici, operazioni commerciali e R&D. Ha supervisionato più di 40 programmi di sviluppo e guidato sette lancio di prodotti di successo in ambiti rari di neurologia e immunologia.
Nelle ultime esperienze in argenx, il Dr. Khan ha guidato l'Area Terapeutica Neuromuscolare, Medical Affairs, dove ha guidato quattro lanci di prodotti VYVGART®. Nei suoi ruoli precedenti ha ricoperto posizioni di leadership in Akouos Inc. e Sarepta Therapeutics, contribuendo a lanciare tre terapie per la distrofia muscolare Duchenne e preparando l'organizzazione Medical Affairs dell'azienda per programmi di terapia genica.
Vor Bio (Nasdaq: VOR) ha nombrado al Dr. Navid Z. Khan como Chief Medical Affairs Officer. Con más de 20 años de experiencia, el Dr. Khan aporta una amplia experiencia en asuntos médicos, operaciones comerciales e I+D. Ha supervisado más de 40 programas de desarrollo y ha liderado siete lanzamientos de productos exitosos en indicaciones raras de neurología e inmunología.
Recientemente en argenx, el Dr. Khan dirigió el Área Terapéutica Neuromuscular, Asuntos Médicos, donde lideró cuatro lanzamientos de productos VYVGART®. Sus roles anteriores incluyen puestos de liderazgo en Akouos Inc. y Sarepta Therapeutics, donde fue clave para lanzar tres terapias de distrofia muscular de Duchenne y para preparar la organización de Asuntos Médicos de la compañía para programas de terapia génica.
Vor Bio (Nasdaq: VOR)가 Dr. Navid Z. Khan을(를) Chief Medical Affairs Officer로 임명했습니다. 20년이 넘는 경력을 가진 Khan 박사는 의학 업무, 상업 운영 및 R&D에 관한 폭넓은 전문 지식을 제공합니다. 그는 40개 이상의 개발 프로그램을 감독했고 희귀 신경학 및 면역학 분야에서 일곱 건의 성공적인 제품 출시를 주도했습니다.
최근 argenx에서 Khan 박사는 Neuromuscular Therapeutic Area, Medical Affairs를 이끌며 VYVGART® 제품의 네 차례 출시를 주도했습니다. Akouos Inc.와 Sarepta Therapeutics에서의 이전 역할에는 Duchenne 무력증 치료제 세 가지의 출시와 유전자 치료 프로그램을 위한 기업의 Medical Affairs 조직 준비에 중요한 기여를 한 바 있습니다.
Vor Bio (Nasdaq : VOR) a nommé Dr. Navid Z. Khan au poste de Chief Medical Affairs Officer. Fort de plus de 20 ans d’expérience, le Dr Khan apporte une expertise approfondie en affaires médicales, opérations commerciales et R&D. Il a supervisé plus de 40 programmes de développement et dirigé sept lancements de produits réussis dans des indications rares en neurologie et immunologie.
Plus récemment chez argenx, le Dr Khan a dirigé l’Area thérapeutique Neuromusculaire, Medical Affairs, où il a orchestré quatre lancements de produits VYVGART®. Ses postes précédents incluent des postes de direction chez Akouos Inc. et Sarepta Therapeutics, où il a joué un rôle clé dans le lancement de trois thérapies pour la dystrophie musculaire de Duchenne et dans la préparation de l’organisation Medical Affairs de l’entreprise pour des programmes de thérapie génique.
Vor Bio (Nasdaq: VOR) hat Dr. Navid Z. Khan zum Chief Medical Affairs Officer ernannt. Mit über 20 Jahren Erfahrung bringt Dr. Khan umfassende Expertise in medizinischen Angelegenheiten, kommerziellen Operationen und F&E mit. Er hat mehr als 40 Entwicklungsprogramme überwacht und sieben erfolgreiche Produkteinführungen in seltenen Indikationen der Neurologie und Immunologie geleitet.
Zuletzt bei argenx leitete Dr. Khan den Neuromuskulären Therapeutikbereich, Medical Affairs, wo er vier Lancierungen der VYVGART®-Produkte vorantrieb. Zu seinen früheren Rollen gehören Führungspositionen bei Akouos Inc. und Sarepta Therapeutics, wo er maßgeblich an der Einführung von drei Duchenne-Muskeldystrophie-Therapien beteiligt war und die Medical Affairs-Organisation des Unternehmens für Gentherapie-Programme vorbereitete.
Vor Bio (بورصة ناسداك: VOR) عيّنت الدكتور نورف ز. خان كـ Chief Medical Affairs Officer. يتمتّع الدكتور خان بأكثر من 20 عامًا من الخبرة، وهو يجلب خبرة واسعة في الشؤون الطبية، والعمليات التجارية، والبحث والتطوير. أشرف على أكثر من 40 برنامج تطوير وقاد سبعة إطلاقات منتجات ناجحة في تخصصات نادرة في مجال الأعصاب والمناعة.
في منصبه الأخير في argenx، قاد الدكتور خان منطقة العلاج العصبي العضلي والشؤون الطبية، حيث قاد أربعة إطلاقات لمنتجات VYVGART®. تشمل أدواره السابقة مناصب قيادية في Akouos Inc. وSarepta Therapeutics، حيث كان له دور أساسي في إطلاق ثلاث علاجات لمرض Duchenne dystrophy العضلي وتحضير تنظيم الشؤون الطبية للشركة لبرامج العلاج الجيني.
Vor Bio（纳斯达克：VOR）任命 Navid Z. Khan 博士为首席医疗事务官。Khan 博士拥有超过20年的经验，在医疗事务、商业运营和研发方面具有广泛专长。他曾监管 40+个开发项目，并在罕见神经科和免疫科适应症领域领导了 七次成功的产品上市。
最近在 argenx 担任 Neuromuscular Therapeutic Area、Medical Affairs 负责人，他推动了四个 VYVGART® 产品的上市。他的前任经历包括在 Akouos Inc. 和 Sarepta Therapeutics 的领导职位，在 Duchenne 肌营养不良症治疗药物的推出方面发挥了关键作用，并为公司在基因治疗项目的 Medical Affairs 组织做了准备。
- Appointment of highly experienced executive with over 20 years in medical affairs, commercial, and R&D
- Track record of seven successful U.S. and global product launches
- Extensive experience in neurology and immunology, aligning with company's focus on autoimmune diseases
- Strong background in gene therapy programs and rare disease treatments
- None.
Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launches
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer.
Dr. Khan joins Vor Bio with over two decades of experience spanning medical affairs, commercial, and R&D functions. He has overseen more than 40 development programs in neurology, immunology, and infectious diseases, and successfully guided seven U.S. and global product launches in rare neurology and immunology indications. Most recently, Dr. Khan was Head of Neuromuscular Therapeutic Area, Medical Affairs at argenx, where he led integrated medical strategy and execution for four launches of VYVGART® and VYVGART Hytrulo®, including two for generalized myasthenia gravis (gMG).
“Navid is an exceptional leader with a proven track record of building world-class medical affairs organizations and executing multiple high-impact product launches,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board of Vor Bio. “His deep scientific expertise, combined with his ability to connect with patients, physicians, and global stakeholders, will be invaluable as we advance telitacicept and shape our broader autoimmune portfolio.”
“I am thrilled to join Vor Bio at such an exciting time,” said Dr. Khan. “Vor has the potential to transform the treatment of autoimmune diseases with telitacicept and beyond. I look forward to working with the talented team to build a best-in-class medical affairs function that ensures strong scientific exchange, evidence generation, and meaningful engagement with the patient and physician communities worldwide.”
Earlier in his career, Dr. Khan held senior leadership positions at Akouos Inc. and Sarepta Therapeutics, where he played a pivotal role in the launch of three Duchenne muscular dystrophy therapies - EXONDYS 51®, VYONDYS 53®, and AMONDYS 45® - and helped transform Sarepta’s Medical Affairs organization in preparation for a wave of gene therapy programs. He also held roles of increasing responsibility at EMD Millipore over more than a decade, spanning R&D, viral vector and vaccine strategy, and commercial leadership.
Dr. Khan earned his Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts, Lowell, and his B.S. in Biochemistry and Molecular Biology from the University of Massachusetts, Amherst.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding Vor Bio’s potential to transform the treatment of autoimmune diseases with telitacicept and beyond and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com
FAQ
Who is the new Chief Medical Affairs Officer at Vor Bio (VOR)?
What is Dr. Navid Khan's experience in product launches?
What was Dr. Khan's role before joining Vor Bio?
What therapeutic areas has Dr. Khan worked in?
What is Vor Bio's main focus as a company?
